TODAY’S TOPIC:

What’s New in Palliative Care Medications (2017) – Drug #6 Brexpiprazole (Rexulti®)

Background:
New medications are constantly being approved by the FDA for the treatment of Indications commonly seen in palliative care

Drug #6: Brexpiprazole (Rexulti®)
- Approved: 2015
- FDA Approved Indication(s):
  - Use as an adjunctive therapy to anti-depressants for the treatment of major depressive disorder
  - Treatment of schizophrenia

Importance:
Antipsychotics are often used in the palliative care population for the management of delirium, nausea, anxiety, insomnia and/or cachexia. It is important for palliative care providers to be aware of this new agent and its role for our patients.

Pharmacology:
Brexipiprazole is an atypical antipsychotic. It is structurally similar to Abilify®

MoA:
Although not completely known, may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.

ADME:
Metabolism mediated by CYP3A4 and CYP2D6. One inactive metabolite: DM-3411. T½: 91 (for brexiprazole) and 86 (for DM-3411) hours

Other Clinical Points:

Warnings and Precautions:
BBW: increased mortality in elderly patients with dementia-related psychosis (as in all antipsychotics)

Dosing:
- In moderate to severe hepatic impairment (CPS ≥ 7), and in moderate to severe or end stage renal impairment (CrCl < 60 mL/min): maximum dose is 2mg and 3mg for MDD and schizophrenia respectively
- In known CYP2D6 poor metabolizers: reduce usual dose by half

ADRs:
- Schizophrenia: Weight increased (≥4% and at least twice the rate for placebo)
- MDD: Weight increased and akathisia (≥5% and at least twice the rate for placebo)

Other Clinical Points:
The efficacy and safety of brexpiprazole were assessed in several published placebo-controlled clinical trials. The first two studies explored the drug’s efficacy and safety in the treatment of schizophrenia and the last two trials discuss its efficacy and safety as an adjunctive treatment for MDD. Here is one in its entirety:

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Palliative Care Pharmacy Team:
Clinical Pharmacy Specialist:
Jenn Pruskowski, PharmD, BCPS, CGP, CPE
pruskowskija@upmc.edu

If you have a topic you would like the pharmacy team to answer, please send your suggestions to:
pruskowskija@upmc.edu

The Literature:
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

- Objective: To assess the efficacy, tolerability, and safety of brexpiprazole as an adjunctive therapy to antidepressant treatments (ADTs) in adults with major depressive disorder (as defined by DSM-IV-TR criteria) and inadequate response to
ADTs
o Methods: phase 3, randomized, placebo-controlled trial. Patients first entered a prospective 8-week phase on physician-determined, open-label ADT. Those with inadequate response were randomized to ADT + brexpiprazole 2 mg/d or ADT + placebo for 6 weeks.

○ Results: Brexpiprazole (n = 175) reduced mean MADRS total score versus placebo (n = 178) at week 6 in the efficacy population per final protocol (6.36 vs. 5.15, P = .0002). Brexpiprazole improved SDS mean score versus placebo (1.15 vs -0.89, p = .0349). The most common treatment-related adverse events were weight gain (brexpiprazole, 8.0%; placebo, 3.1%) and akathisia (7.4% vs 1.0%).

○ Conclusions: “Adjunctive brexpiprazole therapy demonstrated efficacy and was well tolerated in patients with major depressive disorder and inadequate response to ADTS.”

○ Discussion: So remember this medication has only been studied against placebo.

So... What does this all mean Jenn?:
- Yes there is a new atypical antipsychotic on the market – but its role in the palliative care population is small currently.
- Despite its generic name, this medication has a different receptor profile and adverse drug reaction profile than aripiprazole (Abilify®).
- When comparing brexpiprazole to other atypical antipsychotics, it appears to have a similar adverse drug reaction profile as aripiprazole – although more studies are needed to confirm.
- Currently this medication is not available throughout UPMC.
- The cost of brexpiprazole is currently $1122/30 day supply. Most insurance companies do not approve unless the patient has tried at least 2-3 other therapies for schizophrenia or MDD (depending on which indication you are prescribing for).

That concludes “What’s New in Palliative Care Medications”

**CLINICAL PEARL:**
Brexipiprazole (Rexulti) is a new second generation atypical antipsychotic for the management of schizophrenia and major depressive disorder. Its role in palliative care is unclear at this time.